# Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

> **NCT04313660** · PHASE2 · UNKNOWN · sponsor: **Xiaorong Dong** · enrollment: 33 (estimated)

## Conditions studied

- NSCLC
- Anlotinib
- PD-1/L1 Inhibitor

## Interventions

- **DRUG:** Anlotinib In Combination With PD-1/L1 Inhibitor

## Key facts

- **NCT ID:** NCT04313660
- **Lead sponsor:** Xiaorong Dong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04
- **Primary completion:** 2021-02
- **Final completion:** 2022-02
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04313660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04313660, "Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04313660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*